详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]The Center of Gerontology and Geriatrics (National Clinical Research Center for Geriatrics), West China Hospital, Sichuan University, Chengdu, China. [2]School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada. [3]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. [4]Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea. [5]Latin-American Institute of Life and Nature Sciences/Evidence-Based Public Health Research Group, Federal University of Latin-American Integration, Foz do Iguassu, Brazil. [6]Leukemia Program, Cleveland Clinic, Cleveland, Ohio, United States of America. [7]Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. [8]Division of Hematology, The Ohio State University, Columbus, Ohio, United States of America.

出处：

DOI：

摘要：

The prognostic value of age and other non-hematological factors in predicting outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) undergoing antileukemic therapy is not well understood. We performed a systematic review to determine the association between these factors and mortality and health-related quality of life or fatigue among these patients.We searched Medline and Embase through October 2021 for studies in which researchers quantified the relationship between age, comorbidities, frailty, performance status, or functional status; and mortality and health-related quality of life or fatigue in older patients with AML receiving antileukemic therapy. We assessed the risk of bias of the included studies using the Quality in Prognostic Studies tool, conducted random-effects meta-analyses, and assessed the quality of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach.We included 90 studies. Meta-analysis showed that age (per 5-year increase, HR 1.16 95% CI 1.11-1.21, high-quality evidence), comorbidities (Hematopoietic Cell Transplantation-specific Comorbidity Index: 3+ VS less than 3, HR 1.60 95% CI 1.31-1.95, high-quality evidence), and performance status (Eastern Cooperative Oncology Group/ World Health Organization (ECOG/WHO): 2+ VS less than 2, HR 1.63 95% CI 1.43-1.86, high-quality evidence; ECOG/WHO: 3+ VS less than 3, HR 2.00 95% CI 1.52-2.63, moderate-quality evidence) were associated with long-term mortality. These studies provided inconsistent and non-informative results on short-term mortality (within 90 days) and quality of life.High-quality or moderate-quality evidence support that age, comorbidities, performance status predicts the long-term prognosis of older patients with AML undergoing antileukemic treatment.Copyright: © 2022 Hao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

最新[2023]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

第一作者：

第一作者机构： [1]The Center of Gerontology and Geriatrics (National Clinical Research Center for Geriatrics), West China Hospital, Sichuan University, Chengdu, China. [2]School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada. [3]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

通讯作者：

通讯机构： [1]The Center of Gerontology and Geriatrics (National Clinical Research Center for Geriatrics), West China Hospital, Sichuan University, Chengdu, China. [2]School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada. [3]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

推荐引用方式(GB/T 7714)：

APA：

MLA：